Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 31, 2018Journal of Medicinal ChemistryOpen Access

Required Immunoproteasome Subunit Inhibition Profile for Anti-Inflammatory Efficacy and Clinical Candidate KZR-616 ((2S,3R)-N-((S)-3-(Cyclopent-1-en-1-yl)-1-((R)-2-methyloxiran-2-yl)-1-oxopropan-2-yl)-3-hydroxy-3-(4-methoxyphenyl)-2-((S)-2-(2-morpholinoacetamido)propanamido)propenamide)

View Full Paper
Ask AI
Bookmark
Share

Authors

HJHenry W. B. JohnsonUniversity of ArizonaELEric LoweEastern Virginia Medical SchoolJAJanet L. AnderlEnzo Life Sciences (United States)

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Johnson et al. (2018) studied this question.

synapsesocial.com/papers/69d7dc6111d83f35e5ae2ff6https://doi.org/10.1021/acs.jmedchem.8b01201
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Successful treatment of warm-type haemolytic anaemia with bortezomib in a rituximab-failed systemic lupus erythematosus patient2014 · 21 citations
  2. 2Bortezomib induces clinical remission and reduction of ADAMTS 13 inhibitory antibodies in relapsed refractory idiopathic thrombotic thrombocytopenic purpura2013 · 42 citations